Funding
Funding not disclosed
Founders
Product
Problem
Aging is often viewed as an inevitable degenerative process where the body wears out over time. However, emerging scientific data suggests that aging is a biologically controlled process influenced by genes and hormones. This perspective indicates that age-related diseases are regulated by a biological clock, suggesting potential for intervention.
Solution
Ambrosia BioLongevity is a biotechnology company focused on developing therapies that target the underlying biological mechanisms of aging. By identifying and modulating the genes and hormones that control aging, the company aims to slow down the aging process and extend healthy lifespan. Their research is based on the understanding that aging is not simply a degenerative process but a highly choreographed biological event that can be influenced and potentially reversed. Ambrosia BioLongevity is pursuing interventions that address the root causes of aging to combat age-related diseases and promote longevity.
Target Audience
The primary target audience includes individuals interested in extending their healthy lifespan and preventing age-related diseases.
Features
- Researching genes that regulate aging to identify therapeutic targets.
- Developing therapies to modulate hormonal signals that influence aging.
- Investigating mechanisms to slow down or reverse hallmarks of aging.